Identification of polymorphisms of the IκBα gene associated with an increased risk of multiple myeloma

Cancer Genetics and Cytogenetics

Volumn 137, Issue 1, 2002, Pages 43-48

  Parker, Kimberly M ^a,b   Ma, Mark H ^a,b   Manyak, Steven ^a,b   Altamirano, Cibby V ^a,b   Tang, Yong M ^a,b   Frantzen, Malka ^a,b   Mikail, Amy ^a,b   Roussos, Evanthia ^a,b   Sjak Shie, Nelida ^a,b   Vescio, Robert A ^a,b   Berenson, James R ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B ALPHA; DNA BINDING PROTEIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; PRIMER DNA;

ARTICLE; BONE MARROW CELL; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DNA SEQUENCE; EXON; HUMAN; HUMAN CELL; LYMPHOMA; MONONUCLEAR CELL; MULTIPLE MYELOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; CHROMOSOME 14; CHROMOSOME MAP; DRUG ANTAGONISM; GENETIC POLYMORPHISM; GENETICS; POLYMERASE CHAIN REACTION; RISK FACTOR;

BASE SEQUENCE; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 14; DNA PRIMERS; DNA-BINDING PROTEINS; EXONS; HUMANS; I-KAPPA B PROTEINS; MULTIPLE MYELOMA; NF-KAPPA B; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 18644365198     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(02)00541-1     Document Type: Article

References (40)

1. Cabannes E., Khan G., Aillet F., Jarrett R.F., Hay R.T. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. Oncogene. 18:1999;3063-3070.
2. Gilmore T.D., Koedood M., Piffat K.A., White D.W. Rel/NF-kappaB/IkappaB proteins and cancer. Oncogene. 13:1996;1367-1378.
3. Izban K.F., Ergin M., Qin J.Z., Martinez R.L., Pooley R.J., Saeed S., Alkan S. Constitutive expression of NF-kappa B is a characteristic feature of mycosis fungoides. implications for apoptosis resistance and pathogenesis Hum Pathol. 31:2000;1482-1490.
4. Migliazza A., Lombardi L., Rocchi M., Trecca D., Chang C.C., Antonacci R., Fracchiolla N.S., Ciana P., Maiolo A.T., Neri A. Heterogeneous chromosomal aberrations generate 3′ truncations of the NFKB2/lyt-10 gene in lymphoid malignancies. Blood. 84:1994;3850-3860.
5. Rayet B., Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene. 18:1999;6938-6947.
6. Bargou R.C., Leng C., Krappmann D., Emmerich F., Mapara M.Y., Bommert K., Royer H.D., Scheidereit C., Dorken B. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood. 87:1996;4340-4347.
7. Grussel T., Busch W. Experimental studies of the effect of peracetic acid on the endometrium of cattle. Tierarztl Prax. 25:1997;28-34.
8. Barkett M., Gilmore T.D. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene. 18:1999;6910-6924.
9. May M.J., Ghosh S. Signal transduction through NF-kappa B. Immunol Today. 19:1998;80-88.
10. Whiteside S.T., Ernst M.K., LeBail O., Laurent-Winter C., Rice N., Israel A. N- and C-terminal sequences control degradation of MAD3/I kappa B alpha in response to inducers of NF-kappa B activity. Mol Cell Biol. 15:1995;5339-5345.
11. Baeuerle P.A., Baltimore D. NF-kappa B. ten years after Cell. 87:1996;13-20.
12. Matthews J.R., Nicholson J., Jaffray E., Kelly S.M., Price N.C., Hay R.T. Conformational changes induced by DNA binding of NF-kappa B. Nucleic Acids Res. 23:1995;3393-3402.
13. Roulston A., Lin R., Beauparlant P., Wainberg M.A., Hiscott J. Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors. Microbiol Rev. 59:1995;481-505.
14. Davis N., Ghosh S., Simmons D.L., Tempst P., Liou H.C., Baltimore D., Bose H.R. Jr. Rel-associated pp40. an inhibitor of the rel family of transcription factors Science. 253:1991;1268-1271.
15. Haskill S., Beg A.A., Tompkins S.M., Morris J.S., Yurochko A.D., Sampson-Johannes A., Mondal K., Ralph P., Baldwin A.S. Jr. Characterization of an immediate-early gene induced in adherent monocytes that encodes I kappa B-like activity. Cell. 65:1991;1281-1289.
16. Jacobs M.D., Harrison S.C. Structure of an IkappaBalpha/NF-kappaB complex. Cell. 95:1998;749-758.
17. Beg A.A., Baldwin A.S. Jr. The I kappa B proteins. multifunctional regulators of Rel/NF-kappa B transcription factors Genes Dev. 7:1993;2064-2070.
18. Brown K., Park S., Kanno T., Franzoso G., Siebenlist U. Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha. Proc Natl Acad Sci U S A. 90:1993;2532-2536.
19. Henkel T., Machleidt T., Alkalay I., Kronke M., Ben-Neriah Y., Baeuerle P.A. Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B. Nature. 365:1993;182-185.
20. Mellits K.H., Hay R.T., Goodbourn S. Proteolytic degradation of MAD3 (I kappa B alpha) and enhanced processing of the NF-kappa B precursor p105 are obligatory steps in the activation of NF-kappa B. Nucleic Acids Res. 21:1993;5059-5066.
21. Chen F., Sun S.C., Kuh D.C., Gaydos L.J., Demers L.M. Essential role of NF-kappa B activation in silica-induced inflammatory mediator production in macrophages. Biochem Biophys Res Commun. 214:1995;985-992.
22. Palombella V.J., Rando O.J., Goldberg A.L., Maniatis T. The ubiquitin-proteosome pathway is required for processing the NF- kappa B1 precursor protein and the activation of NF-kappa B. Cell. 78:1994;773-785.
23. Rodriguez M.S., Wright J., Thompson J., Thomas D., Baleux F., Virelizier J.L., Hay R.T., Arenzana-Seisdedos F. Identification of lysine residues required for signal-induced ubiquitination and degradation of I kappa B-alpha in vivo. Oncogene. 12:1996;2425-2435.
24. Roff M., Thompson J., Rodriguez M.S., Jacque J.M., Baleux F., Arenzana-Seisdedos F., Hay R.T. Role of IkappaBalpha ubiquitination in signal-induced activation of NFkappaB in vivo. J Biol Chem. 271:1996;7844-7850.
25. Jaffray E., Wood K.M., Hay R.T. Domain organization of I kappa B alpha and sites of interaction with NF- kappa B p65. Mol Cell Biol. 15:1995;2166-2172.
26. Brockman J.A., Scherer D.C., McKinsey T.A., Hall S.M., Qi X., Lee W.Y., Ballard D.W. Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation. Mol Cell Biol. 15:1995;2809-2818.
27. Brown K., Gerstberger S., Carlson L., Franzoso G., Siebenlist U. Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science. 267:1995;1485-1488.
28. DiDonato J., Mercurio F., Rosette C., Wu-Li J., Suyang H., Ghosh S., Karin M. Mapping of the inducible IkappaB phosphorylation sites that signal its ubiquitination and degradation. Mol Cell Biol. 16:1996;1295-1304.
29. Traenckner E.B., Pahl H.L., Henkel T., Schmidt K.N., Wilk S., Baeuerle P.A. Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. Embo J. 14:1995;2876-2883.
30. Sun S., Elwood J., Greene W.C. Both amino- and carboxyl-terminal sequences within I kappa B alpha regulate its inducible degradation. Mol Cell Biol. 16:1996;1058-1065.
31. Andela V.B., Schwarz E.M., Puzas J.E., O'Keefe R.J., Rosier R.N. Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor kappaB. Cancer Res. 60:2000;6557-6562.
32. Huang S., Robinson J.B., Deguzman A., Bucana C.D., Fidler I.J. Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res. 60:2000;5334-5339.
33. Choi S.H., Cho J.Y., Chung Y.S., Hong E., Han Y., Kim S.G. Inhibition of lipopolysaccharide-induced I-kappaB degradation and tumor necrosis factor-alpha expression by acriflavine, an antimicrobial agent. Int J Immunopharmacol. 22:2000;775-787.
34. Gruss H.J., Brach M.A., Herrmann F. Involvement of nuclear factor-kappa B in induction of the interleukin-6 gene by leukemia inhibitory factor. Blood. 80:1992;2563-2570.
35. Sonenshein G.E. Rel/NF-kappa B transcription factors and the control of apoptosis. Semin Cancer Biol. 8:1997;113-119.
36. Ma M., Parker K.M., Mayak S., Altimarino C.et al. Proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma cells to chemotherapeutic agents and overcomes chemo-resistance through inhibition of the NF-κB pathway. Blood. 98(1):2001;473A.
37. Jungnickel B., Staratschek-Jox A., Brauninger A., Spieker T., Wolf J., Diehl V., Hansmann M.L., Rajewsky K., Kuppers R. Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma. J Exp Med. 191:2000;395-402.
38. Beg A.A., Sha W.C., Bronson R.T., Baltimore D. Constitutive NF-kappa B activation, enhanced granulopoiesis, and neonatal lethality in I kappa B alpha-deficient mice. Genes Dev. 9:1995;2736-2746.
39. Hideshima T., Richardson P., Chauhan D., Palombella V.J., Elliott P.J., Adams J., Anderson K.C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61:2001;3071-3076.
40. Stinchcombe T.E., Mitchell B.S., Depcik-Smith N., Orlowski R.Z. PS-341 is active in multiple myeloma. preliminary report of a phase I trial of the proteasome inhibitor PS-341 in patients with hematologic malignancies Blood. 96:2000;516a.